Cargando…

Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report

Poly (ADP-ribose) polymerase inhibitors exhibit strong activity for treating the DNA damage repair defect in patients with prostate carcinoma (PCa). Although conventional DNA-damaging agents can theoretically lead to synthetic antitumoral effects, no report has clearly mentioned the clinical use of...

Descripción completa

Detalles Bibliográficos
Autores principales: Koguchi, Dai, Tabata, Ken-ichi, Tsumura, Hideyasu, Mori, Kohei, Koh, Hideshige, Iwamura, Masatsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175266/
https://www.ncbi.nlm.nih.gov/pubmed/34123730
http://dx.doi.org/10.1016/j.eucr.2021.101712
_version_ 1783703018005331968
author Koguchi, Dai
Tabata, Ken-ichi
Tsumura, Hideyasu
Mori, Kohei
Koh, Hideshige
Iwamura, Masatsugu
author_facet Koguchi, Dai
Tabata, Ken-ichi
Tsumura, Hideyasu
Mori, Kohei
Koh, Hideshige
Iwamura, Masatsugu
author_sort Koguchi, Dai
collection PubMed
description Poly (ADP-ribose) polymerase inhibitors exhibit strong activity for treating the DNA damage repair defect in patients with prostate carcinoma (PCa). Although conventional DNA-damaging agents can theoretically lead to synthetic antitumoral effects, no report has clearly mentioned the clinical use of cisplatin for treating PCa patients with the breast cancer gene (BRCA)2 mutation. We administered 80 mg/m(2) cisplatin triweekly to a patient with metastatic castration-resistant PCa (mCRPC) with the BRCA2 mutation, and after ten cycles, the prostate-specific antigen was dramatically decreased. We suggest that BRCA2 mutations may indicate the use of cisplatin for treating patients with mCRPC.
format Online
Article
Text
id pubmed-8175266
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-81752662021-06-11 Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report Koguchi, Dai Tabata, Ken-ichi Tsumura, Hideyasu Mori, Kohei Koh, Hideshige Iwamura, Masatsugu Urol Case Rep Oncology Poly (ADP-ribose) polymerase inhibitors exhibit strong activity for treating the DNA damage repair defect in patients with prostate carcinoma (PCa). Although conventional DNA-damaging agents can theoretically lead to synthetic antitumoral effects, no report has clearly mentioned the clinical use of cisplatin for treating PCa patients with the breast cancer gene (BRCA)2 mutation. We administered 80 mg/m(2) cisplatin triweekly to a patient with metastatic castration-resistant PCa (mCRPC) with the BRCA2 mutation, and after ten cycles, the prostate-specific antigen was dramatically decreased. We suggest that BRCA2 mutations may indicate the use of cisplatin for treating patients with mCRPC. Elsevier 2021-05-17 /pmc/articles/PMC8175266/ /pubmed/34123730 http://dx.doi.org/10.1016/j.eucr.2021.101712 Text en © 2021 Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Oncology
Koguchi, Dai
Tabata, Ken-ichi
Tsumura, Hideyasu
Mori, Kohei
Koh, Hideshige
Iwamura, Masatsugu
Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report
title Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report
title_full Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report
title_fullStr Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report
title_full_unstemmed Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report
title_short Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report
title_sort effect of cisplatin on metastatic castration-resistant prostate cancer with brca2 mutation: a case report
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175266/
https://www.ncbi.nlm.nih.gov/pubmed/34123730
http://dx.doi.org/10.1016/j.eucr.2021.101712
work_keys_str_mv AT koguchidai effectofcisplatinonmetastaticcastrationresistantprostatecancerwithbrca2mutationacasereport
AT tabatakenichi effectofcisplatinonmetastaticcastrationresistantprostatecancerwithbrca2mutationacasereport
AT tsumurahideyasu effectofcisplatinonmetastaticcastrationresistantprostatecancerwithbrca2mutationacasereport
AT morikohei effectofcisplatinonmetastaticcastrationresistantprostatecancerwithbrca2mutationacasereport
AT kohhideshige effectofcisplatinonmetastaticcastrationresistantprostatecancerwithbrca2mutationacasereport
AT iwamuramasatsugu effectofcisplatinonmetastaticcastrationresistantprostatecancerwithbrca2mutationacasereport